CN107124869B - 包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂 - Google Patents

包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂 Download PDF

Info

Publication number
CN107124869B
CN107124869B CN201580026334.9A CN201580026334A CN107124869B CN 107124869 B CN107124869 B CN 107124869B CN 201580026334 A CN201580026334 A CN 201580026334A CN 107124869 B CN107124869 B CN 107124869B
Authority
CN
China
Prior art keywords
mol
mpla
liposomes
saponin
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580026334.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107124869A (zh
Inventor
C.R.阿尔文
Z.贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of the Army
Original Assignee
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of the Army filed Critical United States Department of the Army
Publication of CN107124869A publication Critical patent/CN107124869A/zh
Application granted granted Critical
Publication of CN107124869B publication Critical patent/CN107124869B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580026334.9A 2014-03-25 2015-03-25 包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂 Active CN107124869B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970118P 2014-03-25 2014-03-25
US61/970118 2014-03-25
PCT/US2015/022461 WO2015148648A1 (en) 2014-03-25 2015-03-25 Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin

Publications (2)

Publication Number Publication Date
CN107124869A CN107124869A (zh) 2017-09-01
CN107124869B true CN107124869B (zh) 2022-04-01

Family

ID=52829375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580026334.9A Active CN107124869B (zh) 2014-03-25 2015-03-25 包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂

Country Status (11)

Country Link
US (1) US10434167B2 (https=)
EP (1) EP3122380B1 (https=)
JP (1) JP6608422B2 (https=)
KR (1) KR102242875B1 (https=)
CN (1) CN107124869B (https=)
AU (1) AU2015236106A1 (https=)
CA (1) CA2943190A1 (https=)
MX (1) MX2016012168A (https=)
RU (1) RU2016141622A (https=)
SG (2) SG11201607396WA (https=)
WO (1) WO2015148648A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015639A1 (en) * 2016-03-09 2017-09-14 Technion Research And Development Foundation Ltd. Liposomal formulations and methods of using same in agriculture
JP6661454B2 (ja) * 2016-04-21 2020-03-11 株式会社東海理化電機製作所 表示装置、表示板の製造方法
EP3618836A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENSAPONINALOGA
US11583578B2 (en) 2017-04-28 2023-02-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery
CN107669692B (zh) * 2017-09-07 2020-09-29 中国人民解放军第二军医大学 Mpla在制备电离辐射致肠道损伤防治药物中的应用
CA3078223A1 (en) * 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2020243166A1 (en) * 2019-05-28 2020-12-03 The Regents Of The University Of California Th1-polarizing adjuvants for enhancing immunogenicity of hiv antigens
CN110613844B (zh) * 2019-10-23 2024-02-27 中国医学科学院生物医学工程研究所 一种迷你联合佐剂纳米颗粒及其制备方法和应用
WO2021126281A1 (en) 2019-12-20 2021-06-24 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
EP3892296A1 (en) * 2020-04-07 2021-10-13 InnoMedica Holding AG Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccine
US20220287970A1 (en) * 2020-06-30 2022-09-15 Eyegene Inc Composition for inhibiting saponin-induced hemolysis, containing cationic liposome
WO2022081707A1 (en) 2020-10-13 2022-04-21 The Government Of The United States, As Represented By The Secretary Of The Army Sars-cov-2 dna vaccine and method of administering thereof
GB2600468A (en) 2020-10-30 2022-05-04 Excivion Ltd Adjuvant composition
CN112546233A (zh) * 2020-12-25 2021-03-26 常州大学 一种负载水不溶性免疫调节分子的透明质酸复合材料及其制备方法
CN114366810B (zh) * 2022-02-15 2024-11-22 中国人民解放军陆军军医大学 一种可高效诱导体液和细胞免疫的天然微生物和植物来源复合双佐剂及其制备方法和应用
EP4493153A1 (en) * 2022-03-14 2025-01-22 Pfizer Inc. Methods for producing an adjuvant
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
IL320955A (en) * 2022-12-13 2025-07-01 Pfizer Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE
WO2025057058A1 (en) * 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
CN117771361B (zh) * 2024-02-27 2024-06-07 天津中逸安健生物科技有限公司 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014454A1 (en) * 1992-12-29 1994-07-07 Entremed, Inc. Vaccines against sterols
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4302459A (en) 1980-03-19 1981-11-24 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
CN1093255A (zh) * 1986-06-17 1994-10-12 恩特雷麦德有限公司 抗甾醇疫苗
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5888519A (en) 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
DK0671948T3 (da) * 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) * 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
SK283760B6 (sk) 1996-10-15 2004-01-08 The Liposome Company, Inc. Farmaceutický prostriedok na dopravu bioaktívnych látok
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008109398A1 (en) * 2007-03-01 2008-09-12 The Catholic University Of America T4 bacteriophage bound to a substrate
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014454A1 (en) * 1992-12-29 1994-07-07 Entremed, Inc. Vaccines against sterols
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate;Beck, Zoltan;《BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES》;20150301;第1848卷(第3期);摘要、图1、图3及图4 *

Also Published As

Publication number Publication date
EP3122380B1 (en) 2025-03-19
US10434167B2 (en) 2019-10-08
KR20170007242A (ko) 2017-01-18
CN107124869A (zh) 2017-09-01
AU2015236106A1 (en) 2016-10-20
EP3122380A1 (en) 2017-02-01
MX2016012168A (es) 2017-04-25
RU2016141622A (ru) 2018-04-25
KR102242875B1 (ko) 2021-04-20
RU2016141622A3 (https=) 2018-10-26
CA2943190A1 (en) 2015-10-01
SG10201808315UA (en) 2018-10-30
WO2015148648A1 (en) 2015-10-01
US20170182152A1 (en) 2017-06-29
JP2017515889A (ja) 2017-06-15
SG11201607396WA (en) 2016-10-28
JP6608422B2 (ja) 2019-11-20

Similar Documents

Publication Publication Date Title
CN107124869B (zh) 包含含有单磷酰脂质a（mpla）的脂质体组合物和皂苷的无毒佐剂制剂
Beck et al. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21
JP2828391B2 (ja) オリゴ糖を表面に有するリポソーム
US20140072616A1 (en) Lyophilization of Virosomes
KR102277013B1 (ko) 아쥬반트화된 비로좀을 제공하는 방법 및 이에 의해 수득가능한 아쥬반트화된 비로좀
Wui et al. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice
US20250177516A1 (en) Methods for producing an adjuvant
US20170165358A1 (en) Methods for enhancing the immunostimulation potency of aluminum salt-absorbed vaccines
JPH05339169A (ja) 経口ワクチン
Matyas Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21
HK40116538A (zh) 制备佐剂的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment